Drug-like compounds are most of the time denied approval and use owing to the unexpected clinical side effects and cross-reactivity observed during clinical trials. These unexpected outcomes resulting in significant ...

Advances in high-throughput sequencing technologies have resulted in an exponential growth of publicly accessible biological datasets. In the ‘big data’ driven ‘post-genomic’ context, much work is being done to explore ...